aspirin has been researched along with Kidney Diseases in 251 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 9.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 9.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)." | 9.07 | Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. ( , 1992) |
| "Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects." | 8.75 | Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 7.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| " There was a lower rate of catheter-associated S aureus bacteremia in patients treated with aspirin versus those not treated with aspirin (0." | 7.74 | Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. ( Bayer, AS; Cheung, AL; Gemery, JM; Remillard, BD; Sedlacek, M, 2007) |
| "The safety of aspirin in heart failure (HF) has been called into question, particularly in those patients (1) without coronary disease, (2) with renal dysfunction, or (3) treated with low-dose angiotensin-converting enzyme (ACE) inhibitors and high-dose aspirin." | 7.73 | Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. ( Armstrong, PW; Fang, J; Ghali, WA; Gong, Y; McAlister, FA; Tu, JV, 2006) |
| "Aspirin reduced the rate of early graft thrombosis of renal transplants in this series but did not improve renal function or graft survival." | 7.71 | Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. ( Metcalfe, M; Murphy, GJ; Nicholson, ML; Taha, R; Windmill, DC, 2001) |
| "Three children with the hemolytic-uremic syndrome were treated with heparin, aspirin, and dipyridamole." | 7.65 | Preliminary report: treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole. ( Arenson, EB; August, CS, 1975) |
| "A review is given on the clinical studies performed with aspirin in patients with chronic vascular occlusions of the limbs and on studies in cerebral ischemia using aspirin and sulfinpyrazone." | 6.14 | Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders. ( Breddin, K, 1977) |
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 5.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "The HOT (Hypertension Optimal Treatment) study randomly assigned participants with diastolic hypertension to aspirin (75 mg) or placebo." | 5.14 | Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. ( Cass, A; Chalmers, J; Gallagher, MP; Jardine, MJ; Lambers Heerspink, HJ; Ninomiya, T; Perkovic, V; Turnbull, F; Zanchetti, A; Zoungas, S, 2010) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 5.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "Low-dose aspirin and diuretics are commonly co-utilized in patients with cardiovascular diseases." | 5.12 | Potential adverse effects of a low-dose aspirin-diuretic combination on kidney function. ( Sweileh, WM, 2007) |
| "During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode." | 5.11 | First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005) |
| "This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)." | 5.07 | Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. ( , 1992) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| " Aspirin and all nonsalicylate NSAIDs share a risk of causing gastric ulcer, upper GI bleeding, and GI perforation." | 4.78 | Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions. ( Greene, JM; Winickoff, RN, 1992) |
| "Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects." | 4.75 | Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 3.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| " There was a lower rate of catheter-associated S aureus bacteremia in patients treated with aspirin versus those not treated with aspirin (0." | 3.74 | Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. ( Bayer, AS; Cheung, AL; Gemery, JM; Remillard, BD; Sedlacek, M, 2007) |
| "The safety of aspirin in heart failure (HF) has been called into question, particularly in those patients (1) without coronary disease, (2) with renal dysfunction, or (3) treated with low-dose angiotensin-converting enzyme (ACE) inhibitors and high-dose aspirin." | 3.73 | Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. ( Armstrong, PW; Fang, J; Ghali, WA; Gong, Y; McAlister, FA; Tu, JV, 2006) |
| "Aspirin reduced the rate of early graft thrombosis of renal transplants in this series but did not improve renal function or graft survival." | 3.71 | Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. ( Metcalfe, M; Murphy, GJ; Nicholson, ML; Taha, R; Windmill, DC, 2001) |
| "Regular use of analgesic drugs containing phenacetin is associated with an increased risk of hypertension and mortality and morbidity due to cardiovascular disease, as well as an increased risk of mortality due to cancer and urologic or renal disease." | 3.68 | An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) ( Dubach, UC; Rosner, B; Stürmer, T, 1991) |
| "Studies with benoxaprofen in rheumatoid arthritis and osteoarthritis, conducted in more than 2000 patients, continue to demonstrate its safety and effectiveness." | 3.66 | An update on long-term efficacy and safety with benoxaprofen. ( Mikulaschek, WM, 1982) |
| "Renal function was studied in 17 patients with rheumatoid arthritis who had each consumed between 5 and 20 kg of aspirin." | 3.65 | Aspirin and analgesic nephropathy. ( Craft, AW; Kerr, DN; Macklon, AF; Thompson, M, 1974) |
| " There was no lysozymuria with severe uraemic heart failure, aspirin and paracetamol poisoning, or severe jaundice, nor in two cases of acute glomerulonephritis." | 3.65 | Lysozymuria and acute disorders of renal function. ( De Silva, KL; Harrison, JF; Parker, RW, 1973) |
| "A survey of 763 patients with rheumatoid arthritis and 145 with osteoarthritis in six clinics in New Zealand showed no association between aspirin intake and a score designed to detect analgesic nephropathy." | 3.65 | Aspirin and the kidney. New Zealand Rheumatism Association Study. ( , 1974) |
| "Three children with the hemolytic-uremic syndrome were treated with heparin, aspirin, and dipyridamole." | 3.65 | Preliminary report: treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole. ( Arenson, EB; August, CS, 1975) |
| "Analgesic nephropathy is part of a wider clinical syndrome associated with the abuse of APC compounds, that is, a minimum total intake of 2 kg of aspirin or phenacetin." | 3.65 | Analgesic nephropathy. ( Nanra, RS, 1976) |
| "In 1255 hemodialysis patients with type 2 diabetes, the German Diabetes Dialysis Study evaluated the effect of atorvastatin (20 mg/d) versus placebo." | 2.75 | Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. ( Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K, 2010) |
| " Documentation is derived from clinical trials, post-marketing surveillance, special studies, and spontaneous reports of adverse drug reactions from foreign countries." | 2.66 | Worldwide safety experience with diclofenac. ( Catalano, MA, 1986) |
| "Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever." | 2.65 | Safety profile: fifteen years of clinical experience with ibuprofen. ( Royer, GL; Seckman, CE; Welshman, IR, 1984) |
| "Angiogenic and non-angiogenic preeclampsia are identified by a sFlt-1PlGF≥85 and<85, respectively, with the risk of maternal and fetal complications at two weeks differing between the two." | 2.61 | [Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians]. ( Achiche, J; Ahriz Saksi, S; Bailleul, S; Boulanger, H; Drouin, D; Dupuis, E; Ekoukou, D; Lefèvre, G; Sault, C; Stawiarski, N, 2019) |
| "Second, new findings about postoperative pain management in patients with preoperative pain and chronic opioid consumption are reported." | 2.48 | Room for improvement: unmet needs in postoperative pain management. ( Pogatzki-Zahn, EM; Schnabel, A; Zahn, PK, 2012) |
| "The differential diagnosis of pulmonary disease should include drug toxicity, progression of the primary illness, and opportunistic infection." | 2.42 | Infiltrative lung disease due to noncytotoxic agents. ( Cooper, JA; Eggert, M; Lock, BJ, 2004) |
| "Normal pregnancy is characterized by a marked reduction in peripheral vascular resistance." | 2.40 | Hypertension in pregnancy. ( Bernheim, J, 1997) |
| " Data are presented in 46 patients who took aspirin continuously for 10 or more years (mean total dosage 35 kg) in whom there was no evidence of significant renal dysfunction." | 2.36 | Aspirin and renal disease. ( Emkey, RD, 1983) |
| "Few large studies have evaluated the adverse events associated with therapeutic colonoscopy for colorectal neoplasia, including bleeding and bowel perforation." | 1.43 | Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan. ( Fushimi, K; Hirata, Y; Koike, K; Matsui, H; Niikura, R; Yamada, A; Yasunaga, H, 2016) |
| " These results suggest that even the acute use of an NSAID (regardless of COX-2 selectivity) can induce gastric damage when combined with the long-term use of low-dose aspirin in an animal model." | 1.43 | Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy. ( Baglie, S; Baller, EM; Franco, GC; Gevert, MV; Lupepsa, AC; Moro, MG; Sanchez, PK; Tostes, AF, 2016) |
| "Overweight and obesity are well-established risk factors for cardiovascular disease and decline in kidney function in individuals with existing chronic kidney disease (CKD)." | 1.33 | Association between body mass index and CKD in apparently healthy men. ( Buring, JE; Gaziano, JM; Gelber, RP; Kausz, AT; Kurth, T; Levey, AS; Manson, JE, 2005) |
| "Dyslipidemia is associated with macular exudates and vision loss." | 1.32 | Preventing diabetic retinopathy through control of systemic factors. ( Fong, D; Jain, A; Sarraf, D, 2003) |
| "Polyarteritis nodosa is a difficult condition to diagnose in a child and can cause brainstem lesions." | 1.32 | Ocular tilt reaction due to a mesencephalic lesion in juvenile polyarteritis nodosa. ( Chong, WK; Dillon, MJ; Elston, J; Harris, CM; Ragge, NK; Taylor, DS, 2003) |
| "Severe bleeding was defined by the need for admission to hospital." | 1.31 | Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. ( Castellino, G; Cuadrado, MJ; Godfrey, T; Hughes, GR; Khamashta, MA, 2001) |
| " Plasma concentrations were measured in four additional animals of all high dose groups after the last dosing at seven time points." | 1.29 | Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. ( Bauer, E; Bauer, M; Greischel, A; Hirsch, U; Lehmann, H; Schmid, J; Schneider, P, 1996) |
| "Women on aspirin, who developed preeclampsia, delivered later in pregnancy [35." | 1.29 | Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. ( Fairley, KF; Ferrier, C; Gamble, G; Kincaid-Smith, P; North, RA, 1995) |
| "The incidence of nausea has increased after LAS administration." | 1.28 | Lysine acetyl salicylic acid in acute renal pain. ( Hanafi, A; Youssef, HA, 1989) |
| " This relationship may represent a dose-response curve relating amount of analgesic intake to prevalence of nephropathy." | 1.27 | Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. ( Buckalew, VM; Schey, HM, 1986) |
| " Patients with this renal disorder require a permanent high dosed indomethacin therapy." | 1.27 | [The significance of renal prostaglandins for kidney function in early childhood]. ( Seyberth, HW, 1987) |
| "Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary PGE2 remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0." | 1.27 | Salicylate nephropathy in the Gunn rat: potential role of prostaglandins. ( Janis, R; Mittman, N; Schlondorff, D, 1985) |
| "Aspirin ingestion was documented by multiple, random, unannounced blood salicylate levels." | 1.26 | Aspirin and analgesic nephropathy. ( Emkey, RD; Mills, JA, 1982) |
| "In patients with preeclampsia the renal excretion of beta 2-microglobulin allows to differentiate between a primary preeclampsia and a preeclampsia superimposed upon chronic pyelonephritis." | 1.26 | Beta 2-microglobulin and other proteins as parameter for tubular function. ( Jaques, G; Keller, M; Mondorf, AW; Prüfer, D; Weise, M, 1981) |
| "Phenacetin was removed from this preparation in 1970 and replaced by an approximately equal amount of ASA (ACC)." | 1.25 | Letter: The clinical course of patients with analgesic nephropathy. ( Gault, MH, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 150 (59.76) | 18.7374 |
| 1990's | 32 (12.75) | 18.2507 |
| 2000's | 37 (14.74) | 29.6817 |
| 2010's | 29 (11.55) | 24.3611 |
| 2020's | 3 (1.20) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, IK | 1 |
| Yen, TH | 1 |
| Guo, YC | 1 |
| Sun, Y | 1 |
| Lien, LM | 1 |
| Chang, WL | 1 |
| Chen, PL | 1 |
| Yang, YC | 1 |
| Sung, FC | 1 |
| Hsu, CY | 1 |
| Diener, HC | 1 |
| Sacco, RL | 1 |
| Easton, JD | 1 |
| Granger, CB | 1 |
| Bar, M | 1 |
| Bernstein, RA | 1 |
| Brainin, M | 1 |
| Brueckmann, M | 1 |
| Cronin, L | 1 |
| Donnan, G | 1 |
| Gdovinová, Z | 1 |
| Grauer, C | 1 |
| Kleine, E | 1 |
| Kleinig, TJ | 1 |
| Lyrer, P | 1 |
| Martins, S | 1 |
| Meyerhoff, J | 1 |
| Milling, T | 1 |
| Pfeilschifter, W | 1 |
| Poli, S | 1 |
| Reif, M | 1 |
| Rose, DZ | 1 |
| Šaňák, D | 1 |
| Schäbitz, WR | 1 |
| Metkus, TS | 1 |
| Qadir, MI | 1 |
| Rehman, A | 1 |
| HamidAkash, MS | 1 |
| Irfan, M | 1 |
| Baber, M | 1 |
| Hussain, SB | 1 |
| Asif, S | 2 |
| Malik, L | 1 |
| Qiu, J | 1 |
| Grine, K | 1 |
| Weise, FK | 1 |
| Bordignon, S | 1 |
| Perrotta, L | 1 |
| Konstantinou, A | 1 |
| Bologna, F | 1 |
| Nagase, T | 1 |
| Chen, S | 1 |
| Chun, KRJ | 1 |
| Schmidt, B | 1 |
| Mudassir, S | 1 |
| Toor, RS | 1 |
| Boulanger, H | 1 |
| Lefèvre, G | 1 |
| Ahriz Saksi, S | 1 |
| Achiche, J | 1 |
| Bailleul, S | 1 |
| Ekoukou, D | 1 |
| Drouin, D | 1 |
| Sault, C | 1 |
| Stawiarski, N | 1 |
| Dupuis, E | 1 |
| Patel, MR | 1 |
| Aboyans, V | 1 |
| Brodmann, M | 1 |
| De Carlo, M | 1 |
| Clement, D | 1 |
| Mazzolai, L | 1 |
| van Bortel, L | 1 |
| van Sambeek, MR | 1 |
| Vlachopoulos, C | 1 |
| Guo, LZ | 1 |
| Kim, MH | 1 |
| Kim, TH | 1 |
| Park, JS | 1 |
| Jin, E | 1 |
| Shim, CH | 1 |
| Choi, SY | 1 |
| Serebruany, VL | 1 |
| Viecelli, AK | 1 |
| Pascoe, EM | 1 |
| Polkinghorne, KR | 1 |
| Hawley, CM | 1 |
| Paul-Brent, PA | 1 |
| Badve, SV | 1 |
| Cass, A | 2 |
| Johnson, DW | 1 |
| Kerr, PG | 1 |
| Mori, TA | 1 |
| Scaria, A | 1 |
| Hooi, LS | 1 |
| Ong, LM | 1 |
| Irish, AB | 1 |
| Niikura, R | 1 |
| Yasunaga, H | 1 |
| Yamada, A | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Hirata, Y | 2 |
| Koike, K | 1 |
| Bouzenna, H | 1 |
| Samout, N | 1 |
| Amani, E | 1 |
| Mbarki, S | 1 |
| Tlili, Z | 1 |
| Rjeibi, I | 1 |
| Elfeki, A | 1 |
| Talarmin, H | 1 |
| Hfaiedh, N | 1 |
| Makam, RC | 1 |
| Erskine, N | 1 |
| McManus, DD | 1 |
| Lessard, D | 1 |
| Gore, JM | 1 |
| Yarzebski, J | 1 |
| Goldberg, RJ | 1 |
| Moro, MG | 1 |
| Sanchez, PK | 1 |
| Gevert, MV | 1 |
| Baller, EM | 1 |
| Tostes, AF | 1 |
| Lupepsa, AC | 1 |
| Baglie, S | 1 |
| Franco, GC | 1 |
| Khedri, M | 1 |
| Szummer, K | 1 |
| Carrero, JJ | 1 |
| Jernberg, T | 1 |
| Evans, M | 1 |
| Jacobson, SH | 1 |
| Spaak, J | 1 |
| Capitanini, A | 1 |
| Tavolaro, A | 1 |
| Rosellini, M | 1 |
| Rossi, A | 1 |
| Sakariassen, KS | 1 |
| Alberts, P | 1 |
| Fontana, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 1 |
| Sorensen, AS | 1 |
| Krane, V | 2 |
| Berger, M | 1 |
| Lilienthal, J | 1 |
| Winkler, K | 1 |
| Schambeck, C | 1 |
| Wanner, C | 2 |
| Uchida, Y | 1 |
| Mori, F | 1 |
| Ogawa, H | 1 |
| Takagi, A | 1 |
| Hagiwara, N | 1 |
| Jardine, MJ | 1 |
| Ninomiya, T | 1 |
| Perkovic, V | 1 |
| Turnbull, F | 1 |
| Gallagher, MP | 1 |
| Zoungas, S | 1 |
| Lambers Heerspink, HJ | 1 |
| Chalmers, J | 1 |
| Zanchetti, A | 1 |
| Wali, RK | 1 |
| Rivera Gorrin, M | 1 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| Bischofs, C | 1 |
| Banya, W | 1 |
| Müller, K | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| May, AE | 1 |
| Flather, M | 1 |
| Gawaz, M | 1 |
| Geisler, T | 1 |
| Bech, FR | 1 |
| Chertow, GM | 1 |
| Dixon, BS | 1 |
| Beck, GJ | 1 |
| Dember, LM | 1 |
| Vazquez, MA | 1 |
| Greenberg, A | 1 |
| Delmez, JA | 1 |
| Allon, M | 2 |
| Himmelfarb, J | 1 |
| Hu, B | 1 |
| Greene, T | 1 |
| Radeva, MK | 1 |
| Davidson, IJ | 1 |
| Ikizler, TA | 1 |
| Braden, GL | 1 |
| Lawson, JH | 1 |
| Cotton, JR | 1 |
| Kusek, JW | 1 |
| Feldman, HI | 1 |
| Hart, RG | 1 |
| Pearce, LA | 1 |
| Asinger, RW | 1 |
| Herzog, CA | 1 |
| Basra, SS | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| Zhang, L | 1 |
| Maya, ID | 1 |
| Bray, MS | 1 |
| Fernandez, JR | 1 |
| Cao, L | 1 |
| Silvestry, S | 1 |
| Zhao, N | 1 |
| Diehl, J | 1 |
| Sun, J | 1 |
| Pogatzki-Zahn, EM | 1 |
| Schnabel, A | 1 |
| Zahn, PK | 1 |
| Choi, YH | 1 |
| Suh, SH | 1 |
| Choi, JS | 1 |
| Kim, CS | 1 |
| Sim, DS | 1 |
| Bae, EH | 1 |
| Lim, SY | 1 |
| Ma, SK | 1 |
| Jeong, MH | 1 |
| Kim, SW | 1 |
| Wong, F | 1 |
| Guignard, JP | 1 |
| Ragge, NK | 1 |
| Harris, CM | 1 |
| Dillon, MJ | 1 |
| Chong, WK | 1 |
| Elston, J | 1 |
| Taylor, DS | 1 |
| Fernandez, JS | 1 |
| Sadaniantz, BT | 1 |
| Sadaniantz, A | 1 |
| HEDWALL, P | 1 |
| HEEG, E | 1 |
| SCOTT, JT | 3 |
| DENMAN, AM | 1 |
| DORLING, J | 1 |
| CLAUSEN, E | 2 |
| STERN, FH | 1 |
| GILMAN, A | 1 |
| MCGUINNESS, BW | 1 |
| DAWBORN, JK | 1 |
| KINCAID-SMITH, P | 4 |
| MCLAREN, J | 1 |
| RAMSAY, AG | 1 |
| WHITE, DF | 1 |
| LABRAM, C | 1 |
| YOUNG, JV | 1 |
| HAYDON, GB | 1 |
| GRAY, CP | 1 |
| HECKER, SP | 1 |
| LEE, PR | 1 |
| GILES, HM | 1 |
| Jain, A | 1 |
| Sarraf, D | 1 |
| Fong, D | 1 |
| Brandt, K | 1 |
| Lock, BJ | 1 |
| Eggert, M | 1 |
| Cooper, JA | 1 |
| Baigent, C | 1 |
| Landray, M | 1 |
| Leaper, C | 1 |
| Altmann, P | 1 |
| Armitage, J | 1 |
| Baxter, A | 1 |
| Cairns, HS | 1 |
| Collins, R | 1 |
| Foley, RN | 1 |
| Frighi, V | 1 |
| Kourellias, K | 1 |
| Ratcliffe, PJ | 1 |
| Rogerson, M | 1 |
| Scoble, JE | 1 |
| Tomson, CR | 1 |
| Warwick, G | 1 |
| Wheeler, DC | 1 |
| Yamamoto, K | 1 |
| Yasunaga, Y | 1 |
| McQueen, MJ | 1 |
| Lonn, E | 1 |
| Gerstein, HC | 1 |
| Bosch, J | 1 |
| Yusuf, S | 1 |
| Gelber, RP | 2 |
| Kurth, T | 2 |
| Kausz, AT | 1 |
| Manson, JE | 1 |
| Buring, JE | 1 |
| Levey, AS | 1 |
| Gaziano, JM | 2 |
| Xu, S | 1 |
| Jiang, B | 1 |
| Maitland, KA | 1 |
| Bayat, H | 1 |
| Gu, J | 1 |
| Nadler, JL | 1 |
| Corda, S | 1 |
| Lavielle, G | 1 |
| Verbeuren, TJ | 1 |
| Zuccollo, A | 1 |
| Cohen, RA | 1 |
| McAlister, FA | 1 |
| Ghali, WA | 1 |
| Gong, Y | 1 |
| Fang, J | 1 |
| Armstrong, PW | 1 |
| Tu, JV | 1 |
| Otrock, ZK | 1 |
| Sawaya, JI | 1 |
| Zebian, RC | 1 |
| Taher, AT | 1 |
| Bertagnolli, MM | 1 |
| Eagle, CJ | 2 |
| Zauber, AG | 2 |
| Redston, M | 1 |
| Solomon, SD | 2 |
| Kim, K | 1 |
| Tang, J | 2 |
| Rosenstein, RB | 2 |
| Wittes, J | 2 |
| Corle, D | 1 |
| Hess, TM | 1 |
| Woloj, GM | 1 |
| Boisserie, F | 1 |
| Anderson, WF | 1 |
| Viner, JL | 1 |
| Bagheri, D | 1 |
| Burn, J | 1 |
| Chung, DC | 1 |
| Dewar, T | 1 |
| Foley, TR | 1 |
| Hoffman, N | 1 |
| Macrae, F | 1 |
| Pruitt, RE | 1 |
| Saltzman, JR | 1 |
| Salzberg, B | 1 |
| Sylwestrowicz, T | 1 |
| Gordon, GB | 1 |
| Hawk, ET | 1 |
| Arber, N | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Zavoral, M | 1 |
| Lechuga, MJ | 1 |
| Gerletti, P | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Fowler, R | 1 |
| Levin, B | 1 |
| Chaussade, S | 1 |
| Avouac, B | 1 |
| Vicaut, E | 1 |
| Valat, JP | 1 |
| Garcia-Donaire, JA | 1 |
| Ruilope, LM | 1 |
| de Silva, R | 1 |
| Nikitin, NP | 1 |
| Witte, KK | 1 |
| Rigby, AS | 1 |
| Loh, H | 1 |
| Nicholson, A | 1 |
| Bhandari, S | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Sedlacek, M | 1 |
| Gemery, JM | 1 |
| Cheung, AL | 1 |
| Bayer, AS | 1 |
| Remillard, BD | 1 |
| Vadivel, N | 1 |
| Trikudanathan, S | 1 |
| Singh, AK | 1 |
| Schaeffner, ES | 1 |
| Bowman, TS | 1 |
| Sweileh, WM | 1 |
| Agodoa, LY | 1 |
| Francis, ME | 1 |
| Eggers, PW | 1 |
| Belibasakis, I | 1 |
| Mazaris, E | 1 |
| Papachristou, C | 1 |
| Kastriotis, I | 1 |
| Weise, M | 1 |
| Prüfer, D | 1 |
| Jaques, G | 1 |
| Keller, M | 1 |
| Mondorf, AW | 1 |
| Royer, GL | 1 |
| Seckman, CE | 1 |
| Welshman, IR | 1 |
| Cinotti, GA | 1 |
| Emkey, RD | 2 |
| Hanks, GW | 1 |
| Clive, DM | 1 |
| Stoff, JS | 1 |
| Foley, RJ | 1 |
| Weinman, EJ | 1 |
| Arroyo, V | 1 |
| Planas, R | 1 |
| Gaya, J | 1 |
| Deulofeu, R | 1 |
| Rimola, A | 1 |
| Pérez-Ayuso, RM | 1 |
| Rivera, F | 1 |
| Rodés, J | 1 |
| Magrini, M | 1 |
| Pavesi, G | 1 |
| Liverta, C | 1 |
| Bruni, G | 1 |
| Hornych, A | 1 |
| Vítko, S | 1 |
| Prát, V | 1 |
| Matousovic, K | 1 |
| Dráb, K | 1 |
| Horcicková, M | 1 |
| Ehrlich, G | 1 |
| Plaza de los Reyes, M | 1 |
| Lazcano, F | 1 |
| Passalacqua, W | 1 |
| Plaza de los Reyes, X | 1 |
| Saffie, A | 1 |
| de Croizet, V | 1 |
| Morin, RJ | 1 |
| Chen, AF | 1 |
| Narayanan, AS | 1 |
| Raye, C | 1 |
| Moss, RA | 1 |
| Srikantaiah, MV | 1 |
| Barajas, L | 1 |
| Axelsen, RA | 1 |
| Henry, MA | 1 |
| Sweet, RS | 1 |
| Tange, JD | 2 |
| Dewanjee, MK | 1 |
| Fuster, V | 1 |
| Rao, SA | 1 |
| Forshaw, PL | 1 |
| Kaye, MP | 1 |
| Nielsen, IL | 2 |
| Rasmussen, S | 2 |
| Petersen, J | 1 |
| Christensen, P | 1 |
| Hilden, T | 2 |
| Birgens, HS | 1 |
| Hansen, MS | 1 |
| Duggin, GG | 2 |
| Mills, JA | 1 |
| Gall, EP | 1 |
| Vanherweghem, JL | 1 |
| Even-Adin, D | 1 |
| Mikulaschek, WM | 1 |
| Briggs, D | 1 |
| Calder, I | 1 |
| Woods, R | 1 |
| Tange, J | 1 |
| Eisinger, AJ | 1 |
| Harbison, RD | 1 |
| Oudart, N | 1 |
| Marcher, K | 1 |
| Lacour, B | 1 |
| Boulu, RG | 1 |
| Guichard, C | 1 |
| Anandan, JV | 1 |
| Matzke, GR | 2 |
| Verheij, M | 1 |
| Stewart, FA | 2 |
| Oussoren, Y | 1 |
| Weening, JJ | 1 |
| Dewit, L | 1 |
| Hamidou, MA | 1 |
| Moreau, A | 1 |
| Jego, P | 1 |
| Testa, A | 1 |
| Banisadr, F | 1 |
| Buzelin, F | 1 |
| Grolleau, JY | 1 |
| Beaufils, M | 1 |
| Uzan, S | 1 |
| Adams, KE | 1 |
| Brown, PA | 1 |
| Heys, SD | 1 |
| Whiting, PH | 1 |
| De Santo, NG | 1 |
| Calò, L | 1 |
| Coppola, S | 1 |
| Anastasio, P | 1 |
| Cantaro, S | 1 |
| Favaro, S | 1 |
| Capasso, G | 1 |
| Borsatti, A | 1 |
| Henrich, WL | 1 |
| Agodoa, LE | 1 |
| Barrett, B | 1 |
| Bennett, WM | 1 |
| Blantz, RC | 1 |
| Buckalew, VM | 3 |
| D'Agati, VD | 1 |
| DeBroe, ME | 1 |
| Eknoyan, G | 2 |
| Lipton, RB | 1 |
| Raskin, N | 1 |
| Ruoff, G | 1 |
| Saper, J | 1 |
| Sheftell, F | 1 |
| Solomon, S | 1 |
| Winchester, JF | 1 |
| North, RA | 1 |
| Ferrier, C | 1 |
| Gamble, G | 1 |
| Fairley, KF | 1 |
| Lehmann, H | 1 |
| Hirsch, U | 1 |
| Bauer, E | 1 |
| Bauer, M | 1 |
| Greischel, A | 1 |
| Schmid, J | 1 |
| Schneider, P | 1 |
| Leslie, GI | 1 |
| Gallery, ED | 2 |
| Arnold, JD | 1 |
| Ross, MR | 1 |
| Gyory, AZ | 1 |
| al-Sahlawi, KS | 1 |
| Tawfik, OM | 1 |
| McGoldrick, MD | 1 |
| Bailie, GR | 1 |
| Delzell, E | 1 |
| Shapiro, S | 1 |
| Bernheim, J | 1 |
| Birbari, AE | 1 |
| Villar, D | 1 |
| Buck, WB | 1 |
| Gonzalez, JM | 1 |
| Oshima, T | 1 |
| Baumeister, M | 1 |
| Aicher, B | 1 |
| Lornoy, W | 1 |
| Becaus, I | 1 |
| Billiouw, JM | 1 |
| Sierens, L | 1 |
| van Kleef, EM | 1 |
| Te Poele, JA | 1 |
| Oussoren, YG | 1 |
| van der Wal, A | 1 |
| Dewit, LG | 1 |
| Murphy, GJ | 1 |
| Taha, R | 1 |
| Windmill, DC | 1 |
| Metcalfe, M | 1 |
| Nicholson, ML | 1 |
| Castellino, G | 1 |
| Cuadrado, MJ | 1 |
| Godfrey, T | 1 |
| Khamashta, MA | 1 |
| Hughes, GR | 1 |
| Muller, DN | 1 |
| Heissmeyer, V | 1 |
| Dechend, R | 1 |
| Hampich, F | 1 |
| Park, JK | 1 |
| Fiebeler, A | 1 |
| Shagdarsuren, E | 1 |
| Theuer, J | 1 |
| Elger, M | 1 |
| Pilz, B | 1 |
| Breu, V | 1 |
| Schroer, K | 1 |
| Ganten, D | 1 |
| Dietz, R | 1 |
| Haller, H | 1 |
| Scheidereit, C | 1 |
| Luft, FC | 1 |
| Aitio, ML | 1 |
| Nakamura, H | 1 |
| Maharaj, R | 1 |
| Campo, A | 1 |
| Mathew, TH | 1 |
| Boss, GR | 1 |
| Seegmiller, JE | 1 |
| George, CR | 2 |
| Clark, WF | 1 |
| Cameron, JS | 1 |
| Emmerson, BT | 1 |
| Proctor, RA | 1 |
| Kunin, CM | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Nanra, RS | 3 |
| Stuart-Taylor, J | 1 |
| de Leon, AH | 1 |
| White, KH | 1 |
| Breddin, K | 1 |
| Dieppe, PA | 2 |
| Huskisson, EC | 1 |
| Prescott, LF | 1 |
| Schreiner, GE | 1 |
| Gault, MH | 5 |
| Wilson, DR | 2 |
| Murray, TG | 1 |
| Goldberg, M | 2 |
| Berio, A | 1 |
| Harker, LA | 2 |
| Hirsh, J | 1 |
| Gent, M | 1 |
| Genton, E | 1 |
| Kennedy, A | 2 |
| Weiss, HJ | 1 |
| Mokotoff, DM | 1 |
| Burns, C | 1 |
| Molland, EA | 1 |
| Christie, D | 1 |
| McPherson, L | 1 |
| Fossati, C | 1 |
| Phillips, BM | 1 |
| Hartnagel, RE | 1 |
| Leeling, JL | 1 |
| Gurtoo, HL | 1 |
| Stewart, JH | 2 |
| McCarthy, SW | 1 |
| Storey, BG | 1 |
| Roberts, BA | 1 |
| Gallery, E | 1 |
| Mahony, JF | 1 |
| Goldberger, LE | 1 |
| Talner, LB | 1 |
| Arenson, EB | 1 |
| August, CS | 1 |
| McIver, MA | 1 |
| Parker, RW | 2 |
| Shaw, RE | 1 |
| Kramer, P | 1 |
| Adams, FG | 1 |
| Murray, RM | 5 |
| Naess, K | 2 |
| Greene, JM | 1 |
| Winickoff, RN | 1 |
| Naruse, T | 1 |
| Burrell, JH | 2 |
| Yong, JL | 2 |
| Macdonald, GJ | 2 |
| Dubach, UC | 3 |
| Rosner, B | 1 |
| Stürmer, T | 1 |
| Shichiri, M | 1 |
| Itoh, H | 1 |
| Iwamoto, H | 1 |
| Marumo, F | 1 |
| Knorr, PA | 1 |
| Woodside, JR | 1 |
| Ruiz, H | 1 |
| Saltzman, B | 1 |
| Zoja, C | 1 |
| Benigni, A | 1 |
| Livio, M | 1 |
| Bergamelli, A | 1 |
| Orisio, S | 1 |
| Abbate, M | 1 |
| Bertani, T | 1 |
| Remuzzi, G | 1 |
| Youssef, HA | 1 |
| Hanafi, A | 1 |
| Sandler, DP | 1 |
| Smith, JC | 1 |
| Weinberg, CR | 1 |
| Dennis, VW | 1 |
| Blythe, WB | 1 |
| Burgess, WP | 1 |
| Schwarz, A | 1 |
| Kunzendorf, U | 1 |
| Keller, F | 1 |
| Offermann, G | 1 |
| Schlegel, SI | 1 |
| Paulus, HE | 1 |
| Ehrich, JH | 1 |
| Wurster, U | 1 |
| Lütge, M | 1 |
| Doehring, E | 1 |
| Oemar, B | 1 |
| Hackenthal, E | 1 |
| Schey, HM | 1 |
| Catalano, MA | 1 |
| Seyberth, HW | 1 |
| Mittman, N | 1 |
| Janis, R | 1 |
| Schlondorff, D | 1 |
| Grzesik, J | 1 |
| Rzymełka, S | 1 |
| Uppington, J | 1 |
| Jobin, F | 1 |
| DeLage, JM | 1 |
| Timbury, GC | 1 |
| Linton, AL | 1 |
| Ohela, K | 1 |
| Ahonen, A | 1 |
| Nakano, J | 1 |
| Wainscoat, JS | 1 |
| Finn, R | 1 |
| Gilchrist, GS | 1 |
| Bailey, RR | 1 |
| Neale, TJ | 1 |
| Little, PJ | 1 |
| Gross, A | 1 |
| Girard, V | 1 |
| Slichter, SJ | 1 |
| Quadracci, LJ | 1 |
| Striker, GE | 1 |
| Rosenmann, E | 1 |
| Dishon, T | 1 |
| Boss, JH | 1 |
| Harrison, JF | 1 |
| De Silva, KL | 1 |
| Petrin, A | 1 |
| Schmidt, R | 1 |
| Burry, HC | 1 |
| Macklon, AF | 1 |
| Craft, AW | 1 |
| Thompson, M | 1 |
| Kerr, DN | 1 |
| Klinenberg, JR | 2 |
| Bluestone, R | 1 |
| Campion, D | 1 |
| Whitehouse, M | 1 |
| Ramsdell, CM | 1 |
| Kelley, WN | 1 |
| Vivaldi, E | 1 |
| Wigley, RD | 1 |
| Champion, GD | 1 |
| Edwards, KD | 2 |
| Schapel, GJ | 1 |
| Jeremy, R | 1 |
| Steele, TW | 1 |
| Calder, IC | 1 |
| Funder, CC | 1 |
| Green, CR | 1 |
| Ham, KN | 1 |
| Barrientos Guzmám, A | 1 |
| Rivas Manga, MC | 1 |
| Llamazares Ortega, C | 1 |
| Hernando Avendaño, L | 1 |
| Bakke, OM | 1 |
| Cammeo, F | 1 |
| Curtis, EA | 1 |
| Stoker, LM | 1 |
| Dalessio, DJ | 1 |
| Rudwal, TC | 2 |
| Redmond, NI | 1 |
| Pinals, RS | 1 |
| Kippen, I | 1 |
| Saluga, PG | 1 |
| Abel, JA | 1 |
| Miley, RA | 1 |
| Heidland, A | 1 |
| Klütsch, K | 1 |
| Spall, M | 1 |
| Frohwein, H | 1 |
| Engles, WD | 1 |
| Dossetor, JB | 1 |
| Jensen, K | 1 |
| Bluemle, LW | 1 |
| Grögler, F | 1 |
| Páramo, PG | 1 |
| Resel, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol[NCT02239120] | Phase 3 | 5,390 participants (Actual) | Interventional | 2014-11-27 | Completed | ||
| RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407] | Phase 4 | 154 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy[NCT00287651] | Phase 2/Phase 3 | 150 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Administrative) | ||
| Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593] | Phase 4 | 9,438 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [NCT00000151] | Phase 3 | 0 participants | Interventional | 1979-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.80 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 5.40 |
Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated. (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.00 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.05 |
"Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.67 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.63 |
Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 3.97 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.71 |
"Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.76 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.91 |
Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, approximately 43 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.09 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.80 |
All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.24 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.28 |
"This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 15.21 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 11.64 |
Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.55 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.93 |
"First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows:~Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or,~Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or,~Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.84 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.33 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 59.7 |
| Apixaban 5 mg | 97.9 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 28.2 |
| Apixaban 5mg | 49.7 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 507 |
| Apixaban 5mg | 868 |
"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 16 |
Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 13 |
"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 27 |
| Warfarin | 29 |
"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Days (Mean) |
|---|---|
| Apixaban | 304.4 |
| Warfarin | 279.6 |
Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 284 |
| Placebo | 352 |
End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 1057 |
| Placebo | 1084 |
Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 526 |
| Placebo | 619 |
Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 213 |
| Placebo | 230 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 701 |
| Placebo | 814 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 639 |
| Placebo | 749 |
Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 131 |
| Placebo | 174 |
42 reviews available for aspirin and Kidney Diseases
| Article | Year |
|---|---|
[Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians].
Topics: Adult; Aspirin; Biomarkers; Endoglin; Endothelium, Vascular; Female; Humans; Immune Tolerance; Infla | 2019 |
The year in cardiology 2014: peripheral circulation.
Topics: Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Biomarkers; Carotid Artery Diseases; Endovascul | 2015 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
Room for improvement: unmet needs in postoperative pain management.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2012 |
Liver and kidney diseases.
Topics: Acetaminophen; Anemia, Sickle Cell; Animals; Aspirin; Cholestasis; Cysts; Glomerulonephritis, IGA; G | 2002 |
Review of antithrombotic agents used for acute coronary syndromes in renal patients.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Fib | 2003 |
[Paracetamol in the treatment of osteoarthritis pain].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxyg | 2003 |
Infiltrative lung disease due to noncytotoxic agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Humans; Hydrochlorothiazide; | 2004 |
[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Contro | 2006 |
Spotlight on renin: cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system.
Topics: Albuminuria; Aspirin; Cardiovascular Diseases; Chronic Disease; Glomerular Filtration Rate; Humans; | 2006 |
Aspirin and renal disease.
Topics: Acetaminophen; Aspirin; Drug Synergism; Humans; Kidney Diseases; Time Factors | 1983 |
Nonprescription analgesics.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemical and Drug Induced Liver Inj | 1983 |
Renal syndromes associated with nonsteroidal antiinflammatory drugs.
Topics: Acute Kidney Injury; Adult; Animals; Anti-Inflammatory Agents; Anuria; Aspirin; Body Water; Electrol | 1984 |
Urate nephropathy.
Topics: Allopurinol; Arthritis; Aspirin; Blood Urea Nitrogen; Glomerular Filtration Rate; Gout; Humans; Kidn | 1984 |
Role of prostaglandins in drug nephrotoxicity.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitor | 1984 |
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
Mechanisms in the development of analgesic nephropathy.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Synergism; Humans; Ki | 1980 |
[Pregnancy nephropathies].
Topics: Adult; Antihypertensive Agents; Aspirin; Epoprostenol; Female; Hemostasis; Humans; Hypertension; Kid | 1993 |
Therapeutic uses of aspirin in renal diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Kidney Diseases; Platelet Aggrega | 1996 |
Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemical | 1997 |
Hypertension in pregnancy.
Topics: Adult; Animals; Antihypertensive Agents; Aspirin; Disease Models, Animal; Eclampsia; Endothelium, Va | 1997 |
Ibuprofen, aspirin and acetaminophen toxicosis and treatment in dogs and cats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1998 |
[Analgesics and kidney].
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibito | 1998 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
Do acetylsalicylic acid and other antiplatelet drugs prevent preeclampsia?
Topics: Aspirin; Autoimmune Diseases; Clinical Trials as Topic; Diabetes Complications; Dose-Response Relati | 2001 |
Hyperuricemia and gout. Classification, complications and management.
Topics: Acute Disease; Allopurinol; Arthritis; Aspirin; Colchicine; Coronary Disease; Diuretics; Gout; Human | 1979 |
The role of platelets in glomerulonephritis.
Topics: Adenosine; Antidepressive Agents; Aspirin; Blood Platelets; Complement System Proteins; Endothelium; | 1975 |
Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.
Topics: Aspirin; Benzbromarone; Benzofurans; Drug Interactions; Fasting; Gout; Humans; Kidney Diseases; Kine | 1977 |
Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia.
Topics: Adult; Age Factors; Aged; Analgesics; Animals; Aspirin; Australia; Caffeine; Drug Combinations; Fema | 1978 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
The third Lilly Prize Lecture. University of London, January, 1979. The nephrotoxicity and hepatotoxicity of antipyretic analgesics.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemical and Drug Induced Liver Inj | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Analgesic nephropathy.
Topics: Acute Kidney Injury; Analgesics; Animals; Arthritis, Rheumatoid; Aspirin; Drug Combinations; Female; | 1975 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Analgesic abuse syndrome: a frequently overlooked cause of reversible renal failure.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine; Diagnosis, Differential; Dr | 1975 |
Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Aspirin; Clinical Prot | 1992 |
Non-steroidal and analgesic therapy in the elderly.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents; Apazone; Aspirin; Cen | 1986 |
[Ototoxic factors requiring consideration in the diagnosis of occupational hearing loss].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Aspirin; Bacterial Infections; Carbon Disulfide; Carbo | 1985 |
The prostaglandins: their significance in clinical practice.
Topics: Abortion, Induced; Anemia, Hemolytic; Animals; Aspirin; Asthma; Chemical Phenomena; Chemistry; Cycli | 1974 |
Chronic effect of analgesics on the kidney.
Topics: Aminopyrine; Analgesics; Animals; Antipyrine; Aspirin; Caffeine; Chronic Disease; Drug Combinations; | 1972 |
Aspirin and the kidney.
Topics: Acetaminophen; Arthritis, Rheumatoid; Aspirin; Humans; Kidney; Kidney Diseases; Kidney Papillary Nec | 1971 |
25 trials available for aspirin and Kidney Diseases
| Article | Year |
|---|---|
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Topics: Aged; Aged, 80 and over; Aspirin; Dabigatran; Double-Blind Method; Female; Fibrinolytic Agents; Huma | 2020 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Dia | 2010 |
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Female; Glom | 2010 |
Use of aspirin associates with longer primary patency of hemodialysis grafts.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Chronic | 2011 |
Warfarin in atrial fibrillation patients with moderate chronic kidney disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Canada; Chi-Square Distributi | 2011 |
Association of factor V gene polymorphism with arteriovenous graft failure.
Topics: Adult; Aged; Aspirin; Chronic Disease; Dipyridamole; DNA; Double-Blind Method; Factor V; Female; Fol | 2012 |
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Comb | 2012 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea | 2005 |
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Fe | 2005 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Blood pressure measures and risk of chronic kidney disease in men.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Blood Pressure; Blood | 2008 |
Potential adverse effects of a low-dose aspirin-diuretic combination on kidney function.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cross-S | 2007 |
Safety profile: fifteen years of clinical experience with ibuprofen.
Topics: Anti-Inflammatory Agents; Aspirin; Blood Cell Count; Blood Coagulation Tests; Blood Proteins; Centra | 1984 |
Intravenous ketoprofen in renal colic: a placebo-controlled pilot study.
Topics: Adult; Aged; Analgesics; Aspirin; Clinical Trials as Topic; Colic; Female; Humans; Ketoprofen; Kidne | 1984 |
Neonatal outcome in a randomized, controlled trial of low-dose aspirin in high-risk pregnancies.
Topics: Aspirin; Chronic Disease; Double-Blind Method; Female; Humans; Hypertension; Infant, Newborn; Kidney | 1995 |
Comparative study of the efficacy of lysine acetylsalicylate, indomethacin and pethidine in acute renal colic.
Topics: Adult; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colic; Doub | 1996 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
Diflunisal and aspirin: a comparison of efficacy and nephrotoxicity in osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Double-Blin | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.
Topics: Adolescent; Adult; Aged; Aspirin; Cerebrovascular Disorders; Diabetes Mellitus; Diabetic Retinopathy | 1992 |
Analgesic use and chronic renal disease.
Topics: Acetaminophen; Adult; Aged; Analgesics; Arthritis; Aspirin; Chronic Disease; Dose-Response Relations | 1989 |
Worldwide safety experience with diclofenac.
Topics: Adult; Aged; Aspirin; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Diclo | 1986 |
[Effect of benzbromarone in uricemia and uricosuria].
Topics: Aspirin; Benzofurans; Chlorothiazide; Clinical Trials as Topic; Colchicine; Drug Combinations; Human | 1972 |
Salicylates in the management of rheumatoid arthritis.
Topics: Aminobenzoates; Arthritis, Rheumatoid; Aspirin; Blood Coagulation; Buffers; Dyspepsia; Gastritis; Ga | 1971 |
186 other studies available for aspirin and Kidney Diseases
| Article | Year |
|---|---|
Antiplatelet agents for the secondary prevention of ischaemic stroke in patients with or without renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Glomerular Filtrat | 2020 |
Searching for the Ideal Antiplatelet Therapy for CABG Patients With Kidney Disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Kidney Diseases; Platelet Aggregation Inhibito | 2022 |
Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Blood Urea Nitrogen; Clopidogrel; Creatinine; Drug The | 2016 |
Protective Effects of Nigella Sativaon Acetylsalicylic Acid-Induced Nephrotoxicity in Albino Rats.
Topics: Animals; Aspirin; Cytoprotection; Kidney Diseases; Nigella sativa; Phytotherapy; Plant Extracts; Pro | 2017 |
Assessing Bleeding Risk in Patients Taking Anticoagulants.
Topics: Age Factors; Alcohol Drinking; Anemia; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Suppor | 2017 |
Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Cathet | 2018 |
Histological Effects of Nigella Sativa on Aspirin-Induced Nephrotoxicity in Albino Rats.
Topics: Animals; Aspirin; Cytoprotection; Humans; Kidney; Kidney Diseases; Male; Nigella sativa; Phytotherap | 2018 |
Renal Dysfunction: The Wake-Up Alarm for Chronic Vascular Disease.
Topics: Aspirin; Factor Xa Inhibitors; Humans; Kidney Diseases; Rivaroxaban; Vascular Diseases | 2019 |
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Fatty Acids, Omega-3; Fish Oils; Humans; Kidney Diseases | 2017 |
Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ce | 2016 |
Protective Effects of Pinus halepensis L. Essential Oil on Aspirin-induced Acute Liver and Kidney Damage in Female Wistar Albino Rats.
Topics: Acute Disease; Albinism; Animals; Aspirin; Chemical and Drug Induced Liver Injury; Female; Kidney; K | 2016 |
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cycl | 2016 |
Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 2017 |
Wunderlich syndrome during antiplatelet drug therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Hematoma; Humans; Kidney Diseases; Leg; Lis | 2009 |
Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Dis | 2010 |
Aspirin and the prevention of cardiovascular disease in chronic kidney disease: time to move forward?
Topics: Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Glomerular Filtration Rate; Hemorrhag | 2010 |
Page kidney Doppler ultrasound.
Topics: Aspirin; Diagnosis, Differential; Diastole; Hematoma; Humans; Hypertension, Renal; Kidney Diseases; | 2011 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
Aspirin and arteriovenous graft thrombosis in hemodialysis: just what the doctor ordered?
Topics: Arteriovenous Shunt, Surgical; Aspirin; Chronic Disease; Dipyridamole; Humans; Kidney Diseases; Plat | 2011 |
Effects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort study.
Topics: Aged; Aspirin; Cardiac Surgical Procedures; Cardiovascular Diseases; Case-Control Studies; Cohort St | 2012 |
The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cycloox | 2002 |
Ocular tilt reaction due to a mesencephalic lesion in juvenile polyarteritis nodosa.
Topics: Aspirin; Brain Diseases; Child, Preschool; Cyclophosphamide; Diplopia; Drug Therapy, Combination; Fe | 2003 |
[Modification of staphylococcal infections of the rat kidney by analgesics].
Topics: Analgesics; Animals; Aspirin; Kidney Diseases; Phenacetin; Rats; Staphylococcal Infections | 1961 |
Renal irritation caused by salicylates.
Topics: Aspirin; Humans; Kidney; Kidney Diseases; Kidney Tubules; Salicylates; Skin Diseases | 1963 |
Nephrotoxic effect of phenacetin and acetylsalicylic acid in animal experiments.
Topics: Animal Experimentation; Animals; Aspirin; Humans; Kidney Diseases; Phenacetin | 1962 |
GOUT. A FIVE-YEAR REVIEW.
Topics: Adrenocorticotropic Hormone; Arthritis; Aspirin; Codeine; Colchicine; Diagnosis, Differential; Diet; | 1963 |
RENAL CHANGES ASSOCIATED WITH ANALGESIC DRUGS.
Topics: Analgesics; Aspirin; Kidney; Kidney Diseases; Phenacetin; Toxicology | 1964 |
ANALGESIC NEPHROTOXICITY; A PHARMACOLOGICAL ANALYSIS.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Antipyrine; Aspirin; Kidney Diseases; Methemoglo | 1964 |
HISTOLOGICAL CHANGES IN RABBIT KIDNEYS INDUCED BY PHENACETIN AND ACETYLSALICYLIC ACID.
Topics: Aspirin; Kidney; Kidney Diseases; Pathology; Pharmacology; Phenacetin; Rabbits; Research; Toxicology | 1964 |
THE EFFECT OF ASPIRIN AND PHENACETIN ON ASCENDING INFECTION IN THE RAT KIDNEY.
Topics: Aspirin; Escherichia coli Infections; Kidney Diseases; Pathology; Pharmacology; Phenacetin; Pyelonep | 1964 |
PHENACETIN NEPHROPATHY.
Topics: Acidosis; Animals; Aspirin; Bacteriuria; Biological Transport; Caffeine; Codeine; Dogs; Drug Therapy | 1965 |
[THERAPEUTIC COMPLICATIONS OF ANALGESIC MEDICATIONS].
Topics: Agranulocytosis; Aminopyrine; Analgesics; Anemia; Anemia, Hemolytic; Aspirin; Drug Hypersensitivity; | 1964 |
NEPHROPATHY ASSOCIATED WITH THE USE OF ANALGESIC MEDICATIONS.
Topics: Acute Kidney Injury; Amobarbital; Analgesics; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Antip | 1965 |
ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA.
Topics: Aspirin; Brain Diseases; Carbohydrate Metabolism; Coma; Fatty Liver; Heart Diseases; Humans; Kidney | 1965 |
Preventing diabetic retinopathy through control of systemic factors.
Topics: Anticoagulants; Aspirin; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Female; G | 2003 |
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Chronic Disease; Disease Progression; Hemorrhage; Hum | 2005 |
Antiplatelet therapy and spontaneous perirenal hematoma.
Topics: Abdominal Pain; Aged; Aspirin; Diagnosis, Differential; Follow-Up Studies; Hematoma; Humans; Ischemi | 2005 |
Association between body mass index and CKD in apparently healthy men.
Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Cohort Stu | 2005 |
The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Arachidonate 12-Lipoxygenase; Aspirin; Diabetes Mellitus, Experimental; | 2006 |
Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ste | 2006 |
Spontaneous abdominal hematoma in a patient treated with clopidogrel and aspirin.
Topics: Abdominal Cavity; Abdominal Pain; Aged; Aspirin; Clopidogrel; Hematoma; Humans; Kidney Diseases; Mal | 2006 |
[NSAIDs and cardiovascular and renal complications].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenas | 2006 |
Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure.
Topics: Aged; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Creatinine; Female | 2007 |
Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aspirin; Bacteremia; Catheters, Indwelling; F | 2007 |
Analgesic nephropathy.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Aspirin; Drug Combinations; Headache; Humans; Kidney | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults.
Topics: Acetaminophen; Adult; Aged; Albuminuria; Analgesics; Aspirin; Cross-Sectional Studies; Female; Glome | 2008 |
Renal colic due to spontaneous perirenal haematoma secondary to antiplatelet medication: two case reports.
Topics: Aspirin; Colic; Hematoma; Humans; Kidney Diseases; Male; Middle Aged; Platelet Aggregation Inhibitor | 2008 |
Beta 2-microglobulin and other proteins as parameter for tubular function.
Topics: Acetaminophen; Amino Acid Sequence; Aspirin; beta 2-Microglobulin; Beta-Globulins; Female; Graft Rej | 1981 |
Clinical assessment of the renal toxicity of antirheumatic drugs.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Dinoprostone | 1984 |
Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion.
Topics: Ascites; Aspirin; Dinoprostone; Diuresis; Glomerular Filtration Rate; Humans; Kidney Diseases; Liver | 1983 |
[Analgesic nephropathy. II. Analgesic nephropathy and analgesic syndrome, diagnosis and treatment].
Topics: Adult; Aspirin; Female; Humans; Kidney Diseases; Male; Middle Aged; Phenacetin; Substance-Related Di | 1984 |
Primary drug therapy: aspirin vs. the nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents; Arthritis; Aspirin; Central Nervous System Diseases; Chemical and Drug Ind | 1983 |
[Combination therapy with prednisone, chlorambucil, dipyridamole and aspirin in various glomerular diseases. Experience with 33 patients].
Topics: Aspirin; Chlorambucil; Dipyridamole; Drug Therapy, Combination; Humans; Kidney Diseases; Prednisone | 1983 |
Platelet adhesion to collagen in normal and von Willebrand's disease subjects.
Topics: Animals; Aspirin; Blood Platelets; Collagen; Diabetes Mellitus; Dipyridamole; Factor VIII; Humans; K | 1980 |
Nephrotoxicity of mild analgesics in the Gunn strain of rat.
Topics: Acetaminophen; Analgesics; Animals; Aspirin; Glucuronosyltransferase; Kidney Diseases; Kidney Medull | 1980 |
A new reproducible experimental model of analgesic nephropathy.
Topics: Acetaminophen; Analgesics; Animals; Antipyrine; Aspirin; Disease Models, Animal; Female; Kidney; Kid | 1983 |
Noninvasive radioisotopic technique for detection of platelet deposition in mitral valve prostheses and quantitation of visceral microembolism in dogs.
Topics: Animals; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Dogs; Embolism; Heart Valve Prosthe | 1983 |
[Acetylsalicylic acid and renal function].
Topics: Adult; Aged; Aspirin; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Mid | 1983 |
Analgesic abuse and the kidney.
Topics: Aged; Analgesics; Aspirin; Caffeine; Codeine; Drug Combinations; Humans; Kidney; Kidney Diseases; Ki | 1980 |
Aspirin and analgesic nephropathy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Creatinine; Female; History, 17th Century; Humans; Kidn | 1982 |
The safety of treating rheumatoid arthritis with aspirin.
Topics: Arthritis, Rheumatoid; Aspirin; Humans; Kidney; Kidney Diseases; Risk; Time Factors | 1982 |
Epidemiology of analgesic nephropathy in Belgium.
Topics: Acetaminophen; Analgesics; Antipyrine; Aspirin; Belgium; Caffeine; Drug Combinations; Humans; Kidney | 1982 |
An update on long-term efficacy and safety with benoxaprofen.
Topics: Alkaline Phosphatase; Anemia; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Humans; Ibup | 1982 |
The influence of metabolic variation on analgesic nephrotoxicity. Experiments with the Gunn rat.
Topics: Acetaminophen; Aminophenols; Aminosalicylic Acids; Analgesics; Animals; Aspirin; Genetic Carrier Scr | 1982 |
Analgesic nephropathy.
Topics: Adult; Analgesics; Aspirin; Female; Humans; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Ph | 1981 |
Acetaminophen as an aspirin substitute: is it safer?
Topics: Acetaminophen; Aspirin; Biotransformation; Cardiomyopathies; Chemical and Drug Induced Liver Injury; | 1980 |
[Urinary N-acetyl-beta-glucosaminidase as index of renal toxicity (author's transl)].
Topics: Acetylglucosaminidase; Animals; Aspirin; Gentamicins; Hexosaminidases; Kidney Diseases; Male; Mice | 1981 |
Nephropathy as a hazard of analgesic abuse.
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents; Aspirin; Female; Humans; Kidney Diseases; Male; M | 1981 |
Acetylsalicylic acid and renal function.
Topics: Aged; Aspirin; Bone Diseases; Creatinine; Female; Giant Cell Arteritis; Glomerular Filtration Rate; | 1980 |
Amelioration of radiation nephropathy by acetylsalicylic acid.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Female; Kidney Diseases; Kidney Function Tests; Mice | 1995 |
Captopril and aspirin in treatment of renal microangiopathy in primary antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Arterioles; Aspirin; Captopril; Drug Therapy, Combination; Female; | 1995 |
Alleviation of experimental cyclosporin A nephrotoxicity by low dose aspirin in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Creatinine; Cyclosporine; Kidney Diseases; Male; Rat | 1993 |
Renal prostaglandins and thromboxane A2 lack a functional significance in the genesis of protein-induced glomerular hyperfiltration in human renal disease.
Topics: Adult; Arachidonic Acids; Aspirin; Dietary Proteins; Dinoprost; Dinoprostone; Female; Glomerular Fil | 1993 |
Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Kidney Diseases | 1996 |
Over-the-counter analgesics and kidney disease.
Topics: Acetaminophen; Analgesics; Aspirin; Drug Combinations; Headache; Humans; Kidney Diseases; Nonprescri | 1996 |
Analgesic nephropathy. Proceedings of a symposium. June 1995.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1996 |
Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease.
Topics: Adult; Anticoagulants; Aspirin; Dipyridamole; Female; Heparin; Humans; Kidney Diseases; Platelet Agg | 1995 |
Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys.
Topics: Acetaminophen; Analgesics; Animals; Aspirin; Blood Cell Count; Body Weight; Caffeine; Central Nervou | 1996 |
Clinical consequences of nonnarcotic analgesic use.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1997 |
Commentary on the National Kidney Foundation position paper on analgesics and the kidney.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; C | 1996 |
Analgesics and the kidney: recommendations of the National Kidney Foundation for the use of analgesics.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; | 1996 |
[Predictive factors for development of hemolytic uremic syndrome (HUS) and early intensive treatments for prevention of HUS enterohemorrhagic Escherichia coli infection].
Topics: Abdominal Pain; Adolescent; Age Factors; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1997 |
Analgesic nephropathy.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Caffeine; Drug Combinations; Drug Interactions; Hu | 1998 |
Analgesic nephropathy: clinical features and pathogenesis. Original data on the incidence and prevalence in a single renal unit.
Topics: Adult; Age Factors; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 1998 |
Influence of acetylsalicylic acid on development of radiation-induced nephropathy.
Topics: Animals; Aspirin; Dose-Response Relationship, Radiation; Edetic Acid; Female; Humans; In Vitro Techn | 2000 |
Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation.
Topics: Aspirin; Biopsy, Needle; Chronic Disease; Cyclooxygenase Inhibitors; Follow-Up Studies; Graft Reject | 2001 |
Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Asp | 2001 |
Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage.
Topics: Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Aspirin; CD4-Positive T-Lym | 2001 |
Acetaminophen, aspirin, and renal failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; K | 2002 |
Analgesic nephropathy.
Topics: Acidosis; Analgesics, Opioid; Aspirin; Australia; Dehydration; Health Education; Humans; Kidney Dise | 1976 |
Acquired causes of hyperuricaemia.
Topics: Alcohol Drinking; Aspirin; Diet; Energy Intake; Gout; Humans; Kidney Diseases; Phenylbutazone; Uric | 1978 |
Salicylate-induced enzymuria: comparison with other anti-inflammatory agents.
Topics: Acetaminophen; Acetylglucosaminidase; Adult; Anti-Inflammatory Agents; Aspirin; Gold; Hexosaminidase | 1978 |
Drug-related nephropathy.
Topics: Analgesics; Aspirin; Heroin Dependence; Humans; Inulin; Kidney; Kidney Cortex Necrosis; Kidney Disea | 1978 |
Nephrotoxicity studies on aspirin and diflunisal.
Topics: Acetylglucosamine; Analgesics; Aspirin; Biphenyl Compounds; Epithelial Cells; Female; Humans; Kidney | 1978 |
Analgesic nephropathy in Canada: clinical syndrome, management, and outcome.
Topics: Adult; Aged; Analgesics; Aspirin; Caffeine; Canada; Codeine; Creatinine; Drug Combinations; Female; | 1978 |
Analgesic-associated nephropathy in the U.S.A.: epidemiologic, clinical and pathogenetic features.
Topics: Acetaminophen; Adult; Aged; Analgesics; Animals; Aspirin; Creatinine; Drug Combinations; Female; Fol | 1978 |
[Nephropathy caused by cystinosis with secondary Bartter's syndrome. Personal experience in a case treated with prolonged diet therapy and acetylsalicylic acid therapy].
Topics: Aspirin; Bartter Syndrome; Child, Preschool; Cystinosis; Female; Humans; Hyperaldosteronism; Infant; | 1978 |
Role of aspirin in renal disease.
Topics: Aspirin; Humans; Kidney; Kidney Diseases; Pain; Phenacetin | 1977 |
Analgesic nephropathy, 1972-76.
Topics: Aspirin; Caffeine; Codeine; Drug Therapy, Combination; Humans; Kidney Diseases; Phenacetin | 1977 |
Phensic addiction.
Topics: Adult; Aspirin; Caffeine; Drug Combinations; Female; Humans; Kidney Diseases; Salicylamides; Substan | 1977 |
Aspirin damage in the rat kidney in the intact animal and after unilateral nephrectomy.
Topics: Animals; Aspirin; Connective Tissue; Connective Tissue Cells; Epithelial Cells; Epithelium; Female; | 1976 |
Analgesics and the kidney: a community-based study.
Topics: Adult; Analgesics; Aspirin; Australia; Female; Humans; Kidney Diseases; Leukocytes; Male; Middle Age | 1976 |
[Side and toxic effects of salicylates].
Topics: Aspirin; Chemical and Drug Induced Liver Injury; Female; Heart Diseases; Humans; Kidney Diseases; Ma | 1976 |
Does aspirin play a role in analgesic nephropathy?
Topics: Animals; Aspirin; Caffeine; Dehydration; Drug Combinations; Female; Hot Temperature; Humidity; Kidne | 1976 |
Analgesic abuse and kidney disease.
Topics: Analgesics; Animals; Aspirin; Australia; Carcinoma, Transitional Cell; Female; Humans; Kidney Diseas | 1976 |
Analgesic nephropathy.
Topics: Acetaminophen; Acute Kidney Injury; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Co | 1976 |
Diseases causing end-stage renal failure in New South Wales.
Topics: Acetaminophen; Adult; Analgesics; Aspirin; Australia; Caffeine; Codeine; Cystoscopy; Female; Glomeru | 1975 |
Letter: Possible role of laxatives in analgesic nephropathy.
Topics: Analgesics; Aspirin; Cathartics; Codeine; Female; Humans; Kidney Diseases; Male; Phenacetin; Substan | 1975 |
Preliminary report: treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole.
Topics: Acute Disease; Anemia, Hemolytic; Aspirin; Blood Platelet Disorders; Blood Platelets; Blood Transfus | 1975 |
Editorial: Analgesic nephropathy: some unsolved problems.
Topics: Analgesics; Animals; Aspirin; Humans; Kidney Diseases; Kidney Papillary Necrosis; Phenacetin; Rats; | 1975 |
The failure of high doses of aspirin to produce renal lesions in pigs.
Topics: Animals; Aspirin; Female; Kidney; Kidney Diseases; Male; Swine | 1975 |
Analgesic abuse in urological practice.
Topics: Acute Kidney Injury; Adult; Aged; Anemia; Aspirin; Codeine; Female; Humans; Hypertension; Kidney Cal | 1975 |
[Analgesic nephropathy].
Topics: Acidosis, Renal Tubular; Analgesics; Aspirin; Autopsy; Caffeine; Creatinine; Drug Interactions; Fema | 1975 |
Letter: The clinical course of patients with analgesic nephropathy.
Topics: Analgesics; Aspirin; Caffeine; Codeine; Creatinine; Female; Follow-Up Studies; Humans; Kidney; Kidne | 1975 |
The radiological diagnosis of analgesic nephropathy.
Topics: Adult; Aged; Aspirin; Atrophy; Calcinosis; Creatinine; Female; Humans; Hydronephrosis; Kidney; Kidne | 1975 |
[Analgesic nephropathy. Interaction between analgetics and laxatives].
Topics: Aspirin; Caffeine; Cathartics; Drug Interactions; Humans; Kidney Diseases | 1976 |
[Kidney diseases associated with hemolytic uremic syndrome,thrombotic thrombocytopenic purpura and disseminated intravascular coagulation].
Topics: Adolescent; Adult; Aspirin; Dipyridamole; Disseminated Intravascular Coagulation; Female; Hemolytic- | 1992 |
Analgesic nephropathy in Fischer 344 rats: comparative effects of chronic treatment with either aspirin or paracetamol.
Topics: Acetaminophen; Animals; Aspirin; Female; Incidence; Kidney Concentrating Ability; Kidney Diseases; K | 1991 |
An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987)
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Hyp | 1991 |
Renal tubular hypouricemia: evidence for defect of both secretion and reabsorption.
Topics: Aged; Aspirin; Creatinine; Furosemide; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubule | 1990 |
Large perirenal hematoma after extracorporeal shock-wave lithotripsy.
Topics: Aged; Aspirin; Blood Coagulation; Hematoma; Humans; Kidney Calculi; Kidney Diseases; Lithotripsy; Ma | 1990 |
Aspirin-induced bilateral renal hemorrhage after extracorporeal shock wave lithotripsy therapy: implications and conclusions.
Topics: Aged; Aspirin; Hemorrhage; Humans; Kidney Calculi; Kidney Diseases; Lithotripsy; Male; Tomography, X | 1990 |
Experimental analgesic nephropathy: changes in renal structure and urinary concentrating ability in Fischer 344 rats given continuous low doses of aspirin and paracetamol.
Topics: Acetaminophen; Animals; Aspirin; Body Weight; Disease Models, Animal; Female; Kidney Concentrating A | 1990 |
Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease.
Topics: Animals; Aspirin; Blood Platelets; Kidney; Kidney Diseases; Kidney Glomerulus; Male; Platelet Aggreg | 1989 |
Lysine acetyl salicylic acid in acute renal pain.
Topics: Acute Disease; Adult; Analgesics; Aspirin; Colic; Dose-Response Relationship, Drug; Drug Evaluation; | 1989 |
Analgesic use and chronic renal disease.
Topics: Acetaminophen; Analgesics; Aspirin; Chronic Disease; Data Collection; Humans; Kidney Diseases; Phena | 1989 |
Progression of renal failure in analgesic-associated nephropathy.
Topics: Acetaminophen; Adult; Aged; Analgesics; Aspirin; Creatinine; Female; Humans; Kidney; Kidney Diseases | 1989 |
[Enzymuria and kidney diseases in childhood].
Topics: Acetylglucosaminidase; Adolescent; Aminopeptidases; Anti-Bacterial Agents; Aspirin; CD13 Antigens; C | 1986 |
[Adverse effects of non-steroidal antirheumatic drugs with special reference to the gastrointestinal tract].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Drug Hypersensitivity; Gast | 1987 |
Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Kidney; Kidney Diseases; Kidney Failure, C | 1986 |
[The significance of renal prostaglandins for kidney function in early childhood].
Topics: Angiotensin II; Aspirin; Child, Preschool; Creatinine; Ductus Arteriosus, Patent; Glomerular Filtrat | 1987 |
Salicylate nephropathy in the Gunn rat: potential role of prostaglandins.
Topics: Animals; Aspirin; Dinoprostone; Heterozygote; Homozygote; In Vitro Techniques; Kidney Concentrating | 1985 |
Anesthetic management of patients with coagulation disorders.
Topics: Anesthetics; Anticoagulants; Aspirin; Blood Coagulation; Blood Coagulation Disorders; Cardiopulmonar | 1985 |
Aspirin and prednisone in microangiopathic haemolytic anaemia.
Topics: Adult; Anemia, Hemolytic; Aspirin; Blood Platelet Disorders; Blood Urea Nitrogen; Erythrocytes, Abno | 1970 |
Analgesic abuse in psychiatric patients.
Topics: Adult; Aged; Anemia; Aspirin; Creatinine; Dyspepsia; Female; Humans; Kidney Diseases; Male; Mental D | 1970 |
[Kidney toxicity of analgesics].
Topics: Acetaminophen; Administration, Oral; Aspirin; Humans; Kidney Diseases; Long-Term Care; Phenacetin | 1973 |
[Drug eruptions and anaphylactic reactions at a Finnish central hospital].
Topics: Adolescent; Adult; Age Factors; Aged; Ampicillin; Analgesics; Anaphylaxis; Angioedema; Anti-Bacteria | 1972 |
Possible role of laxatives in analgesic nephropathy.
Topics: Adult; Aged; Analgesics; Arthritis, Rheumatoid; Aspirin; Cathartics; Codeine; Creatinine; Drug Combi | 1974 |
Platelet disorders.
Topics: Antibody Formation; Aspirin; Blood Cell Count; Blood Coagulation Disorders; Blood Coagulation Tests; | 1972 |
Analgesic nephropathy and aspirin.
Topics: Analgesics; Aspirin; Female; Humans; Kidney Diseases; Male; Phenacetin; Substance-Related Disorders | 1974 |
Analgesic nephropathy.
Topics: Adult; Aged; Analgesics; Anemia; Aspirin; Codeine; Drug Combinations; Female; Follow-Up Studies; Hum | 1974 |
Personality factors in analgesic nephropathy.
Topics: Adult; Aged; Analgesics; Aspirin; Creatinine; Extraversion, Psychological; Female; Gastrointestinal | 1974 |
A kinetic evaluation of hemostasis in renal disease.
Topics: Aspirin; Blood Coagulation; Complement System Proteins; Diabetic Nephropathies; Dipyridamole; Fibrin | 1974 |
Urinary excretion of kidney antigens in rats consuming analgesics.
Topics: Animals; Antigens; Aspirin; Diet; Female; Immune Sera; Immunodiffusion; Kidney Diseases; Kidney Tubu | 1972 |
The use and abuse of analgesics.
Topics: Analgesics; Aspirin; Female; Humans; Kidney Diseases; Male; Mental Disorders; Scotland; Self Medicat | 1972 |
Lysozymuria and acute disorders of renal function.
Topics: Acetaminophen; Acute Disease; Aspirin; Electroshock; Glomerulonephritis; Heart Failure; Humans; Hypo | 1973 |
Toxic nephropathies.
Topics: Aspirin; Gentamicins; Humans; Kidney Diseases; Methoxyflurane; Phenacetin | 1973 |
[Adverse effects of acetylosalicylic acid].
Topics: Aspirin; Gastrointestinal Diseases; Humans; Hypoglycemia; Kidney Diseases | 1973 |
[Risks in long-term treatment with analgesics].
Topics: Acetaminophen; Analgesics; Antipyrine; Aspirin; Caffeine; Diuresis; Drug Combinations; Humans; Kidne | 1973 |
Drug-induced nephropathies.
Topics: Animals; Arthritis, Rheumatoid; Aspirin; Colic; Complement System Proteins; Glomerular Filtration Ra | 1973 |
Aspirin and analgesic nephropathy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Blood Pressure; Creatinine; Female; Humans; Kidney Dise | 1974 |
Aspirin and the kidney. New Zealand Rheumatism Association Study.
Topics: Acetaminophen; Adult; Arthritis, Rheumatoid; Aspirin; Caffeine; Codeine; Drug Synergism; Female; Hum | 1974 |
The binding of urate to plasma proteins.
Topics: Allopurinol; Aspirin; Binding Sites; Blood Proteins; Colchicine; Dialysis; Evaluation Studies as Top | 1974 |
The clinical significance of hypouricemia.
Topics: Allopurinol; Amino Acids; Aspirin; Autoanalysis; Creatinine; Glycosuria; Humans; Kidney Diseases; Ne | 1974 |
Editorial: Choice of a mild analgesic.
Topics: Acetaminophen; Aspirin; Drug Combinations; Humans; Kidney Diseases; Phenacetin; Substance-Related Di | 1974 |
Effect of chronic administration of analgesics on resistance to experimental infection of the urinary tract in rats.
Topics: Acetaminophen; Animals; Aspirin; Bacteriuria; Escherichia coli Infections; Female; Foreign Bodies; K | 1968 |
[Enzyme determinations in nephrologic diagnosis].
Topics: Adolescent; Adult; Aspirin; Clinical Enzyme Tests; Glucosidases; Graft Rejection; Humans; Isoenzymes | 1970 |
Possible nephrotoxicity of aspirin in rheumatoid arthritis.
Topics: Age Factors; Arthritis, Rheumatoid; Aspirin; Glomerular Filtration Rate; Humans; Kidney Diseases | 1972 |
Possible nephrotoxicity of aspirin in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Caffeine; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Ph | 1972 |
Analgesic nephropathy: removal of phenacetin from proprietary analgesics.
Topics: Analgesics; Aspirin; Caffeine; Codeine; Drug Combinations; Humans; Kidney Diseases; Phenacetin; Scot | 1972 |
Clinical cases of renal calculi.
Topics: Adult; Aerospace Medicine; Aspirin; Depression; Female; Humans; Kidney Calculi; Kidney Diseases; Mal | 1971 |
Acetaminophen, valadol, and analgesic renal injury.
Topics: Acetaminophen; Analgesics; Aspirin; Humans; Kidney Diseases; Kidney Papillary Necrosis; Nephritis, I | 1971 |
Comparative nephrotoxicity of aspirin and phenacetin derivatives.
Topics: Aniline Compounds; Animals; Aspirin; Female; Kidney; Kidney Diseases; Kidney Papillary Necrosis; Kid | 1971 |
[Kidney disease caused by analgesics].
Topics: Adult; Analgesics; Aspirin; Codeine; Female; Humans; Kidney Diseases; Male; Phenacetin; Phenobarbita | 1971 |
["Phenacetin-kidney" or "analgetic-nephropathy"].
Topics: Acetaminophen; Aspirin; Humans; Kidney Diseases; Phenacetin | 1971 |
[Determination of uric acid in blood. Experimental determination; critical studies of the technics and results].
Topics: Adolescent; Adult; Aspirin; Autoanalysis; Female; Gout; Humans; Indicators and Reagents; Kidney Dise | 1971 |
One-day renal function testing in normal rats and in cases of experimentally-induced analgesic nephropathy, nephrocalcinosis and nephrotic syndrome.
Topics: Animals; Aspirin; Caffeine; Citrates; Creatinine; Female; Hydrogen-Ion Concentration; Kidney; Kidney | 1971 |
Headache nostrums and chronic illness.
Topics: Analgesics; Aspirin; Chronic Disease; Gastrointestinal Hemorrhage; Headache; Kidney Diseases; Monoam | 1966 |
Analgesic habits of 500 veterans: incidence and complications of abuse.
Topics: Adult; Aged; Analgesics; Anemia; Arthritis; Aspirin; Caffeine; Canada; Codeine; Gastrointestinal Hem | 1968 |
Aspirin and alternatives.
Topics: Adult; Analgesics; Anti-Inflammatory Agents; Aspirin; Fever; Gastrointestinal Hemorrhage; Humans; In | 1970 |
The binding of urate to plasma proteins determined by means of equilibrium dialysis.
Topics: Aspirin; Blood Proteins; Dialysis; Gout; Humans; Hydrogen-Ion Concentration; Hypoxanthines; Kidney D | 1970 |
[Analgetics and kidney damage].
Topics: Analgesics; Animals; Aspirin; Humans; Kidney Diseases; Nicotine; Phenacetin; Rats | 1970 |
Urinary cytology in experimental toxic renal injury.
Topics: Acute Kidney Injury; Animals; Aspirin; Azirines; Chromates; Eosinophils; Histocytochemistry; Kidney | 1970 |
Phenacetin nephropathy.
Topics: Acetaminophen; Animals; Aspirin; Caffeine; Humans; Kidney Diseases; Phenacetin; Rats | 1970 |
Reye's syndrome and salicylate intoxication.
Topics: Adipose Tissue; Aspirin; Brain Diseases; Chemical and Drug Induced Liver Injury; Fatty Liver; Humans | 1970 |
[Clinical and experimental studies on the phenacetin kidney].
Topics: Aminohippuric Acids; Animals; Aspirin; Diuresis; Dogs; Guinea Pigs; Humans; Inulin; Kidney Diseases; | 1967 |
Syndrome associated with the abuse of analgesics.
Topics: Adult; Age Factors; Analgesics; Anemia; Animals; Aspirin; Caffeine; Cats; Dogs; Female; Guinea Pigs; | 1968 |
Renal biopsies from patients with a high analgesic intake. Histological and bacteriological study.
Topics: Adult; Aspirin; Biopsy; Female; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Kidney Tubul | 1968 |
Statement on analgesic nephropathy.
Topics: Analgesics; Animals; Aspirin; Australia; Caffeine; Drug and Narcotic Control; Drug Labeling; Female; | 1969 |
Renal accumulation of salicylate and phenacetin: possible mechanisms in the nephropathy of analgesic abuse.
Topics: Analgesics; Animals; Aspirin; Dehydration; Dogs; Female; Humans; Hydrogen-Ion Concentration; Kidney; | 1969 |
[Acute kidney damage after a suicide attempt with tablets containing phenacetin].
Topics: Adult; Aspirin; Humans; Kidney Diseases; Male; Phenacetin; Suicide | 1965 |
[Medicamentous (toxico-allergic) nephropathies].
Topics: Aspirin; Humans; Kidney; Kidney Diseases; Middle Aged | 1965 |
Phenacetin, aspirin, and kidney damage.
Topics: Animals; Aspirin; Humans; Kidney Diseases; Phenacetin; Rabbits; Rats | 1966 |